Proteomic analysis for developing new biomarkers of hepatocellular carcinoma

Figure 1 Eight spots were differentially expressed when HCC samples were compared with non-HCC samples by proteomics analysis.

Figure 2 Plasma levels of Apo-A1, Apo-A4 and Apo-E in controls and HCC patients. Apo-A4 was significantly higher in patients without HCC than in patients with HCC (2.1 ± 0.4 vs 1.4 ± 0.5; ^bP < 0.01).

Figure 3 ROC curve from the logistic equation. The AUROC is 0.91 with a cut-off level of 0.35; with an 89% sensitivity and a 91% specificity for diagnosis of HCC.

Figure 4 Risk curve of hepatocellular carcinoma for different values of one apolipoprotein and a fixed level of the other apolipoproteins. A: Risk of HCC for different Apo-A1 levels and fixed Apo-A4 level (mean); B: Risk of HCC for different Apo-A4 levels and fixed Apo-A1 level (mean); C: Risk of HCC for different Apo-A1 levels and fixed Apo-A4 level (maximum); D: Risk of HCC for different Apo-A1 levels and fixed Apo-A4 level (minimum).